FMO5 and lung disorder: In vivo and in vitro experimental studies have demonstrated that simvastatin could reduce oxidative stress in many lung diseases by inhibiting the GTPases (Rac) pathway and inactivating the NADPH oxidase system at a cellular level, reducing ROS generation [54].